Ambit Biosciences Corp (AMBI)

Ambit Biosciences Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of oncology, autoimmune, and inflammatory diseases in the United States. The company’s products include quizartinib, an orally administered FMS-like tyrosine kinase inhibitor that has completed Phase II clinical trials for the treatment of patients with relapsed and refractory acute myeloid leukemia. Its drug candidates also comprise AC410, a small molecule inhibitor of Janus kinase 2, which is in Phase 1 clinical trials; and AC708, a receptor tyrosine kinase inhibitor that is in pre-clinical studies for the treatment of oncology, autoimmune, and inflammatory diseases. The company has collaboration agreements with Astellas Pharma Inc. to research, develop, and commercialize various FLT3 kinase inhibitors; Cephalon, Inc. to identify and develop clinical candidates that target the BRAF kinase and a second kinase; and Genoptix, Inc. to develop a laboratory diagnostic test to identify patients that harbor ITD mutations in their FLT3 receptor tyrosine kinase. Ambit Biosciences Corporation was formerly known as Aventa Biosciences Corporation and changed its name to Ambit Biosciences Corporation in November 2001. The company was incorporated in 2000 and is based in San Diego, California. As of November 10, 2014, Ambit Biosciences Corporation operates as a subsidiary of Daiichi Sankyo Company, Limited.